• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Vigil Neuroscience Inc.

    10/9/24 6:22:58 PM ET
    $VIGL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VIGL alert in real time by email
    SC 13D/A 1 d835577dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT

    TO RULE 13d-2(a)

    (Amendment No. 1)*

     

     

    Vigil Neuroscience, Inc.

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    92673K108

    (CUSIP Number)

    Jean-Philippe Kouakou-Zebouah

    Chief Financial Officer

    Vida Ventures, LLC

    40 Broad Street, Suite 201

    Boston, MA 02109

    (415)-378-9984

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    August 13, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

     

     

     


    CUSIP No. 92673K108   13D

     

     1.    

     Name of Reporting Persons

     

     Vida Ventures GP III, L.L.C.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     AF

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.    

     Sole Voting Power

     

     0

        8.  

     Shared Voting Power

     

     5,015,929 shares of Common Stock (1)

        9.  

     Sole Dispositive Power

     

     0

       10.  

     Shared Dispositive Power

     

     5,015,929 shares of Common Stock (1)

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     5,015,929 shares of Common Stock (1)

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row 11

     

     12.7% (2)

    14.  

     Type of Reporting Person (See Instructions)

     

     OO

     

    (1)

    Consists of (i) 5,004,393 shares held by Vida III (as defined in Item 2(a) of the Original Schedule 13D (as defined below)) and (ii) 11,536 shares held by Vida III-A (as defined in Item 2(a) of the Original Schedule 13D). Vida III GP (as defined in Item 2(a) of the Original Schedule 13D) is the general partner of each of Vida III and Vida III-A and may be deemed to have voting, investment, and dispositive power with respect to these securities. Arie Belldegrun, Helen Kim, Arjun Goyal, Rajul Jain and Stefan Vitorovic, a member of the Issuer’s board of directors, are the members of the investment committee of Vida III GP (the “Investment Committee”). Each of the Investment Committee and the members thereof may be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based upon 39,647,533 shares of the Issuer’s Common Stock outstanding as of July 31, 2024, as set forth in the Issuer’s quarterly report on Form 10-Q for the quarter ended June 30, 2024, filed with the Securities and Exchange Commission (“Commission”) on August 13, 2024 (the “Form 10-Q”).


    CUSIP No. 92673K108   13D

     

     1.    

     Name of Reporting Persons

     

     Vida Ventures III, L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     WC

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.    

     Sole Voting Power

     

     0

        8.  

     Shared Voting Power

     

     5,004,393 shares of Common Stock (1)

        9.  

     Sole Dispositive Power

     

     0

       10.  

     Shared Dispositive Power

     

     5,004,393 shares of Common Stock (1)

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     5,004,393 shares of Common Stock (1)

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row 11

     

     12.6% (2)

    14.  

     Type of Reporting Person (See Instructions)

     

     PN

     

    (1)

    These shares are held by Vida III. Vida III GP is the general partner of Vida III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Each of the Investment Committee and the members thereof may be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based upon 39,647,533 shares of the Issuer’s Common Stock outstanding as of July 31, 2024, as reported in the Form 10-Q.


    CUSIP No. 92673K108   13D

     

     1.    

     Name of Reporting Persons

     

     Vida Ventures III-A, L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     WC

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.    

     Sole Voting Power

     

     0

        8.  

     Shared Voting Power

     

     11,536 shares of Common Stock (1)

        9.  

     Sole Dispositive Power

     

     0

       10.  

     Shared Dispositive Power

     

     11,536 shares of Common Stock (1)

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     11,536 shares of Common Stock (1)

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row 11

     

     0.0% (2)

    14.  

     Type of Reporting Person (See Instructions)

     

     PN

     

    (1)

    These shares are held by Vida III-A. Vida III GP is the general partner of Vida III-A and may be deemed to have voting, investment, and dispositive power with respect to these securities. Each of the Investment Committee and the members thereof may be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based upon 39,647,533 shares of the Issuer’s Common Stock outstanding as of July 31, 2024, as reported in the Form 10-Q.


    CUSIP No. 92673K108   13D

     

     1.    

     Name of Reporting Persons

     

     Stefan Vitorovic

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     AF

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     United States of America

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.     

     Sole Voting Power

     

     26,083 shares (1)

        8.   

     Shared Voting Power

     

     5,015,929 shares of Common Stock (2)

        9.   

     Sole Dispositive Power

     

     26,083 shares (1)

       10.   

     Shared Dispositive Power

     

     5,015,929 shares of Common Stock (2)

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     5,042,012 shares of Common Stock (1) (2)

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row 11

     

     12.7% (3)

    14.  

     Type of Reporting Person (See Instructions)

     

     IN

     

    (1)

    Represents 26,083 shares subject to stock options granted to Mr. Vitorovic in his capacity as a director of the Issuer that are exercisable as of the date of the filing of this Amendment No. 1 (as defined below) or within 60 days thereafter. Excludes 18,068 shares subject to stock options granted to Mr. Vitorovic and that are not exercisable within 60 days of the filing of this Amendment No. 1.

    (2)

    Includes all securities held of record by Vida III and Vida III-A. Vida III GP is the general partner of each of Vida III and Vida III-A and may be deemed to share voting, investment and dispositive power with respect to these securities. Mr. Vitorovic, a member of the Issuer’s board of directors, is a member of the Investment Committee and may be deemed to share voting, investment and dispositive power with respect to these securities.

    (3)

    Based upon 39,647,533 shares of the Issuer’s Common Stock outstanding as of July 31, 2024, as reported in the Form 10-Q, plus 26,083 shares subject to stock options held by Mr. Vitorovic and that are exercisable as of the date of the filing of this Amendment No. 1 or within 60 days thereafter.


    CUSIP No. 92673K108   13D

     

    Explanatory Note

    This Amendment No. 1 to Schedule 13D (“Amendment No. 1”) amends and supplements the Schedule 13D initially filed by the Reporting Persons with the Securities and Exchange Commission (the “Commission”) on February 10, 2023 (the “Original Schedule 13D”). Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13D remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment have the meanings ascribed to them in the Original Schedule 13D.

    Item 1. Security and Issuer

    This Amendment No. 1 is filed with respect to the Issuer’s Common Stock. The address of the principal executive offices of the Issuer is 100 Forge Road, Suite 700, Watertown, MA 02472. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

    Item 5. Interest in Securities of the Issuer.

    Solely on behalf of, and only to the extent that it relates to the Reporting Persons, Items 5(a) and 5(b) of the Original Schedule 13D is hereby amended as follows:

    The information reported on the cover page of each Reporting Person, except Mr. Vitorovic, is based on a total of 39,647,533 shares of the Issuer’s Common Stock outstanding as of July 31, 2024, as reported in the Form 10-Q filed with the Commission on August 13, 2024.

    The information reported on the cover page of Mr. Vitorovic is based on a total of 39,673,616 shares, comprised of (i) 39,647,533 shares of the Issuer’s Common Stock outstanding as of July 31, 2024, as reported in the Form 10-Q filed with the Commission on August 13, 2024 and (ii) 26,083 shares of the Issuer’s Common Stock underlying fully vested stock options granted to Mr. Vitorovic for service as a member of the Issuer’s board of directors.

    This Amendment No. 1 is being filed to update the aggregate percentage of the Issuer’s Common Stock owned by the Reporting Persons due to dilution caused by, among other things, the Issuer’s sales of additional shares of its Common Stock from time to time since the date of the filing of the Original Schedule 13D and not in connection with any transaction in the Issuer’s securities by the Reporting Persons. Such dilution resulted in a decrease of over one percent (1%) in the aggregate percentage ownership reported by the Reporting Persons in the Original Schedule 13D.

    (a) and (b) See Items 7-11 and 13 of the cover pages of this Amendment No. 1 for each Reporting Person and Item 2 above.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: October 9, 2024
    VIDA VENTURES III, L.P.
    By:   Vida Ventures GP III, L.L.C.
    Its:   General Partner
    By:  

    /s/ Stefan Vitorovic

      Stefan Vitorovic, Managing Member
    VIDA VENTURES III-A, L.P.
    By:   Vida Ventures GP III, L.L.C.
    Its:   General Partner
    By:  

    /s/ Stefan Vitorovic

      Stefan Vitorovic, Managing Member
    VIDA VENTURES GP III, L.L.C.
    By:  

    /s/ Stefan Vitorovic

      Stefan Vitorovic, Managing Member

    /s/ Stefan Vitorovic

    Stefan Vitorovic
    Get the next $VIGL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VIGL

    DatePrice TargetRatingAnalyst
    12/4/2024Outperform
    William Blair
    12/19/2023$13.00 → $4.00Equal-Weight → Underweight
    Morgan Stanley
    10/18/2023$23.00Mkt Outperform
    JMP Securities
    3/31/2023$15.00Buy
    Mizuho
    9/16/2022$19.00Outperform
    Wedbush
    8/29/2022$24.00Buy
    H.C. Wainwright
    2/1/2022$17.00Equal-Weight
    Morgan Stanley
    2/1/2022$23.00Buy
    Guggenheim
    More analyst ratings

    $VIGL
    Leadership Updates

    Live Leadership Updates

    See more
    • Augustine Therapeutics appoints Gerhard Koenig as Chief Executive Officer as Company Prepares to Enter the Clinic

      Augustine Therapeutics appoints Gerhard Koenigas Chief Executive Officer as Company Prepares to Enter the Clinic Industry veteran Gerhard Koenig, PhD, current Executive Chairman, appointed as CEOBest-in-class highly selective HDAC6 inhibitor pioneer for disease-modifying treatment of neuromuscular, neurodegenerative and cardiometabolic diseases poised to enter the clinic LEUVEN, Belgium – February 13, 2025 – Augustine Therapeutics ("Augustine" or "the Company"), a preclinical-stage biotechnology company focused on innovative therapies for neuromuscular, neurodegenerative and cardiometabolic diseases through the inhibition of the cytosolic Histone DeACetylase 6 (HDAC6) enzyme, today announc

      2/13/25 7:00:00 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Augustine Therapeutics Raises EUR 17 Million in a Series A First Closing to Advance Lead Candidate Into Clinical Development in Neurological Diseases

      Proceeds will advance lead candidate AGT100216, a peripherally restricted and selective HDAC6 inhibitor, into a first-in-human clinical Phase 1/2 study Gerhard Koenig appointed as executive chairman of Augustine's Board of Directors Augustine Therapeutics, a pioneering biotech company focused on novel treatments for neurodegenerative and cardiometabolic diseases, today announced that it has raised EUR 17 million (USD 18.5 million) in the first closing of its Series A round. The financing was led by Asabys Partners, with participation from Eli Lilly and Company, and the US-based Charcot-Marie-Tooth Research Foundation. Current investors AdBio partners, V-Bio Ventures, PMV, VIB and Gem

      6/26/24 1:00:00 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update

      – Enrollment completed for Phase 2 trial evaluating iluzanebart in ALSP; Next data readout planned for Q3 2024 – – Phase 1 healthy volunteer trial evaluating VG-3927 for Alzheimer's disease ongoing; Interim data analysis on track for mid-2024 – WATERTOWN, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the first quarter ended March 31, 2024, and provided an update on recent progress. "During the quarter, we continued to progress iluzanebart, our monoclonal antibody, and VG-3927, our or

      5/7/24 4:05:00 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIGL
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Vigil Neuroscience Inc.

      DEFA14A - Vigil Neuroscience, Inc. (0001827087) (Filer)

      5/22/25 4:36:58 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Vigil Neuroscience Inc.

      DEFA14A - Vigil Neuroscience, Inc. (0001827087) (Filer)

      5/22/25 4:35:49 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Vigil Neuroscience Inc.

      DEFA14A - Vigil Neuroscience, Inc. (0001827087) (Filer)

      5/22/25 4:34:29 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIGL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Budd Haeberlein Samantha L. bought $20,520 worth of shares (12,000 units at $1.71) (SEC Form 4)

      4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

      12/19/24 6:44:11 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Magovcevic-Liebisch Ivana bought $8,400 worth of shares (5,000 units at $1.68), increasing direct ownership by 2% to 222,687 units (SEC Form 4)

      4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

      12/19/24 6:42:45 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Magovcevic-Liebisch Ivana bought $8,350 worth of Common Stock (5,000 units at $1.67), increasing direct ownership by 2% to 217,687 units (SEC Form 4)

      4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

      12/18/24 5:51:48 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIGL
    Financials

    Live finance-specific insights

    See more
    • Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

      - Vigil's shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 - - Acquisition expected to strengthen development path for the oral small molecule TREM2 agonist program, including VG-3927, a Phase 2-ready clinical candidate for potential treatment of Alzheimer's disease – - Companies expect transaction to close in third quarter of 2025 - WATERTOWN, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for

      5/21/25 7:30:46 PM ET
      $SNY
      $VIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Vigil Neuroscience Announces Interim Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating VGL101 in Healthy Volunteers Supporting Phase 2 Initiation in ALSP

      VGL101 demonstrated favorable safety, tolerability and PK profiles in single ascending dose and multiple ascending dose cohortsVGL101 achieved dose dependent, robust and durable decreases in CSF sTREM2 demonstrating proof of target engagement further validating its mechanism of action On track to initiate Phase 2 trial with a 20 mg/kg dose of VGL101 in ALSP patients this quarterCompany to host conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced interim topline r

      11/2/22 7:00:00 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Medical Officer Kaufmann Petra

      4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

      3/4/25 5:09:51 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Bruhn Suzanne Louise

      4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

      3/4/25 5:09:31 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Ziolkowski Jennifer Lynn

      4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

      3/4/25 5:09:35 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Vigil Neuroscience

      William Blair initiated coverage of Vigil Neuroscience with a rating of Outperform

      12/4/24 7:51:48 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vigil Neuroscience downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Vigil Neuroscience from Equal-Weight to Underweight and set a new price target of $4.00 from $13.00 previously

      12/19/23 7:39:43 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JMP Securities initiated coverage on Vigil Neuroscience with a new price target

      JMP Securities initiated coverage of Vigil Neuroscience with a rating of Mkt Outperform and set a new price target of $23.00

      10/18/23 7:41:08 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIGL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

      - Vigil's shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 - - Acquisition expected to strengthen development path for the oral small molecule TREM2 agonist program, including VG-3927, a Phase 2-ready clinical candidate for potential treatment of Alzheimer's disease – - Companies expect transaction to close in third quarter of 2025 - WATERTOWN, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for

      5/21/25 7:30:46 PM ET
      $SNY
      $VIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates

      – On track to report final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP in Q2 2025 – – Plans to initiate Phase 2 clinical trial evaluating VG-3927 in Alzheimer's disease in Q3 2025 – WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the first quarter ending March 31, 2025, and provided updates on its recent progress. "During the quarter, we continued to make meaningful progress across our two TREM2 programs, VG-3927 and iluzanebart," said Ivana Ma

      5/7/25 7:00:00 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference

      - Preclinical presentation highlights key, modality specific, pharmacological differentiations of VG-3927 - - First presentation of topline clinical data from Phase 1 SAD/MAD trial of VG-3927 for the potential treatment of Alzheimer's disease (AD) - WATERTOWN, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today presented data highlighting its oral small molecule program, including its lead clinical candidate VG-3927, in two oral presentations at the AD/PD™ 2025 International Conference on Alzheimer's and Parkinson's Dis

      4/2/25 7:00:00 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIGL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Vigil Neuroscience Inc.

      SC 13G/A - Vigil Neuroscience, Inc. (0001827087) (Subject)

      11/14/24 4:19:18 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Vigil Neuroscience Inc.

      SC 13G/A - Vigil Neuroscience, Inc. (0001827087) (Subject)

      11/14/24 10:00:07 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Vigil Neuroscience Inc.

      SC 13D/A - Vigil Neuroscience, Inc. (0001827087) (Subject)

      10/9/24 6:22:58 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care